Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
With the increased availability of next-generation sequencing, oncologists are starting to
incorporate genomic profiling into routine care of cancer patients. If a genomic alteration
is identified during profiling, it could help guide the choice of therapy and improve
treatment outcomes. This study will examine the anti-tumor activity of selected commercially
available molecularly matched targeted therapies in patients who have failed first-line
treatment for one of the following tumor types: non-small cell lung cancers; urothelial
cancer; non-colon gastrointestinal cancers, and upper aerodigestive tract cancer.
Phase:
Phase 2
Details
Lead Sponsor:
SCRI Development Innovations, LLC
Collaborators:
Bayer Boehringer Ingelheim Exelixis Foundation Medicine